Compare McCormick & Company, Incorporated (MKC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs TG Therapeutics Inc — how do they compare? McCormick & Company, Incorporated trades at $44.87 (market cap $12.39B), while TG Therapeutics Inc trades at $54.85 (market cap $8.16B). The key difference: McCormick & Company, Incorporated is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and TG Therapeutics Inc for 16 Days on average.
| MKC | TGTX | |
|---|---|---|
Market Cap | $12.39B | $8.16B |
Volume | 6,140,872 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $59.06 |
52-Week Low | $44.14 | $26.94 |
Typical Hold Time | 67 Days | 16 Days |
Enterprise Value | $17.07B | $8.37B |
Dividend Yield | 4.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.005, down 0.54% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q3 2026 results with 17% sales growth and margin expansion, supported by the McCormick de Mexico acquisition. Valuation metrics appear attractive with a P/E of 8.31 and net income margin of 19.39%, while analyst consensus shows a mixed but predominantly hold rating.
The stock presents value opportunities with below-sector P/E ratios and consistent dividend payments, but faces technical headwinds and competitive pressures. Upside potential exists toward the $53.50 consensus target, though investors should monitor integration execution and consumer spending trends given the bearish technical indicators and mixed analyst sentiment.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
